Technology | Leads Implantable Devices | May 06, 2019

FDA Approves Attain Stability Quad MRI SureScan Lead from Medtronic

First quad active-fixation left heart lead designed for precise placement and stability

FDA Approves Attain Stability Quad MRI SureScan Lead from Medtronic

May 6, 2019 — Medtronic has received U.S. Food and Drug Administration (FDA) approval for the Attain Stability Quad MRI SureScan left heart lead. Paired with Medtronic quadripolar cardiac resynchronization therapy-defibrillators (CRT-D) and -pacemakers (CRT-P), the Attain Stability Quad lead is the only active-fixation left heart lead, according to the company, and is designed for precise lead placement and stability. The lead will be commercially available in the U.S. in summer 2019.

"Appropriate placement of left heart leads during implantation of CRT devices is critical to achieve the clinical benefits of this therapy. Unfortunately, with present passive-fixation leads, we are not always able to position the lead in an ideal location due to variations in a patient's anatomy and size of the target vessel. We also continue to see lead dislodgements that require reprogramming or repeat surgery for lead repositioning. Having a new active fixation left heart lead allows us to target the ideal location in the patient's vessel with the confidence that the lead will remain in place to allow for continued effective delivery of CRT," said Steven Zweibel, M.D., F.A.C.C., F.H.R.S., C.C.D.S., director of electrophysiology at the Hartford Healthcare Heart and Vascular Institute (Conn.).

CRT is a treatment for heart failure in which an implantable device sends low levels of energy through thin wires, called leads, to stimulate the heart muscle and potentially improve the heart's pumping efficiency. With the introduction of quadripolar leads (leads with four electrodes), physicians can pace from different locations in the heart, but are limited in where they can place the lead. The Attain Stability Quad lead integrates the benefits of a quadripolar lead with a side-helix that allows physicians to fixate the lead precisely in veins of various sizes, including ones not typically amenable to positioning a passive lead. Additionally, patients with this lead and MR-conditional CRT devices are eligible for either 3 Tesla (T) and 1.5T magnetic resonance imaging (MRI) scans, if needed.

For more information: www.medtronic.com

Related Content

News | EP Lab

January 14, 2022 — Medtronic has entered into a definitive agreement to acquire Affera Inc., a Boston area-based ...

Home January 14, 2022
Home
News | EP Lab

January 13, 2022 — Abbott received U.S. Food and Drug Administration (FDA) clearance for the EnSite X EP System with ...

Home January 13, 2022
Home
News | EP Lab

January 7, 2022 — Khaldoun Tarakji, M.D., M.P.H., associate section head of cardiac electrophysiology at the Heart ...

Home January 07, 2022
Home
News | EP Lab

January 5, 2022 — Stereotaxis announced a recent publication in Frontiers in Cardiovascular Medicine titled “Atrial ...

Home January 05, 2022
Home
Feature | EP Lab

Children’s Hospital Los Angeles cardiologist Michael Silka, M.D., helped to pioneer the development of indications for ...

Home December 07, 2021
Home
News | EP Lab

November 22, 2021 — BioSig Technologies Inc., a medical technology company commercializing an innovative biomedical ...

Home November 22, 2021
Home
Videos | EP Lab

Christine Albert, M.D., MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz ...

Home November 22, 2021
Home
Feature | EP Lab

November 18, 2021 — The U.S. Food and Drug Administration (FDA) is reminding providers about the risk of major ...

Home November 18, 2021
Home
News | EP Lab

November 16, 2021 — Acutus Medical Inc. (Acutus), an arrhythmia management company focused on improving the way cardiac ...

Home November 16, 2021
Home
News | EP Lab

November 15, 2021 — Vektor Medical Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Home November 15, 2021
Home
Subscribe Now